Reviewnpj drug discovery2026
Proportionate evidence in biosimilar development: when a comparative efficacy study can still change the regulatory conclusion.
Review in npj drug discovery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Biosimilar regulation was established using a systematic, stepwise framework in which clinical comparisons addressed residual uncertainties following comprehensive quality and pharmacokinetic assessments. Advances in analytical resolution, clinical pharmacology, and over two decades of regulatory expertise have substantially mitigated this residual uncertainty. This publication examines circumstances in which a comparative efficacy study could still influence regulatory decisions. It presents four original analyses: a quantitative comparison of the nominal resolution of selected analytical methodologies, combined with predefined equivalence criteria, within specific clinical programs that operate at disparate scales and are used solely to demonstrate respective resolution and acceptance thresholds. Additionally, an audit of publicly available regulatory outcomes identifies 100 United States 351(k)-licensed biosimilar and interchangeable products, alongside 149 authorized European biosimilars. It also classifies 16 European nonpositive initial outcomes: nine primarily driven by quality, manufacturing, or product bridging issues; two involving clinical pharmacology or overall comparability; one following a positive opinion; and four lacking sufficient public detail. Notably, no case identified a failed comparative efficacy study as the sole decisive factor, a conclusion limited by excluding programs abandoned before filing from the dataset. An analysis of participant burden estimates indicates an aggregate of more than 10,000 enrollments for programs approved through 2019. A Bayesian value of information model shows that, under a defined base case, the net benefit of such a study diminishes once prior evidence indicates that clinical similarity substantially exceeds the decision threshold. The framework continues to emphasize targeted clinical evidence relevant to unresolved mechanisms, uncharacterized local exposure, potential immune risks, or unaddressed population-specific questions.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.